Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: Evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region

Genes Chromosomes and Cancer

Volumn 45, Issue 5, 2006, Pages 495-508

  Flahaut, Marjorie ^a   Mühlethaler Mottet, Annick ^a   Martinet, Danielle ^a   Fattet, Sarah ^b   Bourloud, Katia Balmas ^a   Auderset, Katya ^a   Meier, Roland ^a   Schmutz, Nathalie Besuchet ^a   Delattre, Olivier ^b   Joseph, Jean Marc ^a   Gross, Nicole ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; CISPLATIN; CYTOCHROME C; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROCASPASE 3; PROCASPASE 7; PROCASPASE 8; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL2L1; PROTEIN MDM2; PROTEIN P53; PROTEIN RIP; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; STAUROSPORINE; UNCLASSIFIED DRUG; VERAPAMIL;

AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME 7Q; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG TRANSPORT; GENE; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENOMICS; HUMAN; HUMAN CELL; MDR1 GENE; MULTIDRUG RESISTANCE; NEURAL CREST; NEUROBLASTOMA; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 7; DNA PRIMERS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; POLYMERASE CHAIN REACTION;

EID: 33645829589     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20312     Document Type: Article

References (58)

1. Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire JA. 2003. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 5:53-62.
2. Blanc E, Goldschneider D, Fetrandis E, Barrois M, Le RG, Leonce S, Douc-Rasy S, Benard J, Raguenez G. 2003. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol 163:321-33.
3. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL. 1996. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149:1941-1952.
4. Brodeur GM. 2003 Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203-216.
5. Calvet L, Santos A, Valent A, Terrier-Lacombe MJ, Opolon P, Merlin JL, Aubert G, Morizet J, Schellens JH, Benard J, Vassal G. 2004. No topoisomerase I alteration in a neurobiastoma model with in vivo acquired resistance to irinotecan. Br J Cancer 91:1205-1212.
6. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J. 2004. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 5:70.
7. Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA. 1989. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 49:219-225.
8. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. 1992. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7:127-133.
9. De PK, Speleman F, Combaret V, Lunec J, Board J, Pearson A, De PA, Van RN, Laureys G, Vandesompele J. 2005. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol 23:3167-3168.
10. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP. 1995. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55:2576-2582.
11. Evan G, Littlewood T. 1998. A matter of life and cell death. Science 281:1317-1322.
12. Ferry DR, Traunecker H, Kerr DJ. 1996. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070-1081.
13. Flahaut M, Mühlethaler-Mottet A, Auderset K, Balmas Bourloud K, Meier R, Joseph JM, Beck Popovic M and Gross N 2005. Persistent inhibition of FLIPL expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells. Apoptosis, in press.
14. Fix A, Peter M, Pierron G, Aurias A, Delattre O, Janoueix-Lerosey I. 2004. High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hybridization. Genes Chromosomes Cancer 40:266-270.
15. Fulda S, Lutz W, Schwab M, Debatin KM. 1999. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18:1479-1486.
16. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y. 2005. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 3:325-334.
17. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transportets. Nat Rev Cancer 2:48-58.
18. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD. 1997. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 33:2031-2036.
19. Hiemstra JL, Schneider SS, Brodeur GM. 1994. High-resolution mapping of the N-myc amplicon core domain in neuroblastomas. Prog Clin Biol Res 385:51-57.
20. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. 2000. Loss of caspase-8 expression in highly-malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60:4315-4319.
21. Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL, Gross N. 2002. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-in-dependent in N-type cells. Oncogene 21:6132-6137.
22. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. 1999. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523-14528.
23. Kirchhoff M, Gerdes T, Maahr J, Rose H, Bentz M, Dohner H, Lundsteen C. 1999. Deletions below 10 megabasepairs are detected in comparative genomic hybridization by standard reference intervals. Genes Chromosomes Cancer 25:410-413.
24. Kirchhoff M, Gerdes T, Maahr J, Rose H, Lundsteen C. 1997. Automatic correction of the interfering effect of unsuppressed interspersed repetitive sequences in comparative genomic hybridization analysis. Cytometry 28:130-134.
25. Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, Lundsteen C. 1998. Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Cytometry 31:163-173.
26. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, Kohno K. 2003. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 94:9-14.
27. Lee WP, Lee CL. 1994. Characterization of vincristine-resistant HOB1 lymphoma cell line showing the classical MDR phenotype and altered expression of membrane glycoproteins. Oncology 51:2-8.
28. Li D, Jang SH, Kim J, Wientjes MG, Au JL. 2003. Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res 20:45-50.
29. Longley DB, Johnston PG. 2005. Molecular mechanisms of drug resistance. J Pathol 205:275-292.
30. Lowe SW, Ruley HE, Jacks T, Housman DE. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
31. Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C, Marshall GM, Norris MD, Haber M, Cohn SL. 2004. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23:753-762.
32. McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD, Schofield AC. 2005. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 41:1086-1094.
33. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. 1997. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 99:1947-1957.
34. Mora J, Cheung NK, Oplanich S, Chen L, Gerald WL. 2002. Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res 62:1761-1767.
35. Muhlethaler-Mottet A, Bourloud KB, Auderset K, Joseph JM, Gross N. 2004. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-x(L) and RIP. Oncogene 23:5415-5425.
36. Norris MD, Bordow SB, Haber PS, Marshall GM, Kavallaris M. Madafiglio J, Cohn SL, Salwen H, Schmidt ML, Hipfner DR, Cole SP, Deeley RG, Haber M. 1997. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur J Cancer 33:1911-1916.
37. Pajic M, Norris MD, Cohn SL, Haber M. 2005. The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Lett. 228:241-246
38. Pauli-Magnus C, von RO, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF. 2000. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 293:376-382.
39. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207-211.
40. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D. 1991. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51:6529-6538.
41. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper R. 2000. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550-556.
42. Scott D, Elsden J, Pearson A, Lunec J. 2003. Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype? Cancer Lett 197:81-86.
43. Seeger RC, Rayner SA, Banerjee A, Chung H, Laug WE, Neustein HB, Benedict WF. 1977. Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res 37:1364-1371.
44. Slovak ML, Hoeltge GA, Trent JM. 1987. Cytogenetic alterations associated with the acquisition of doxorubicin resistance: possible significance of chromosome 7 alterations. Cancer Res 47:6646-6652.
45. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. 2001. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211.
46. Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. 2001. Survival of children with neuroblastoma, time trends and regional differences in Europe, 1978-1992. Eur J Cancer 37:722-729.
47. Stallings RL, Howard J, Dunlop A, Mullarkey M, McDermott M, Breatnach F, O'Meara A. 2003. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? Cancer Genet Cytogenet 140:133-137.
48. Struski S, Cornillet-Lefebvre P, Doco-Fenzy M, Dufer J, Ulrich E, Masson L, Michel N, Gruson N, Potron G. 2002. Cytogenetic characterization of chromosomal rearrangement in a human vinblastine-resistant CEM cell line: use of comparative genomic hybridization and fluorescence in situ hybridization. Cancer Genet Cytogenet 132:51-54.
49. Thomas H, Coley HM. 2003. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159-165.
50. Trent JM, Witkowski CM. 1987. Clarification of the chromosomal assignment of the human P-glycoprotein/mdr1 gene: possible coincidence with the cystic fibrosis and c-met oncogene. Cancer Genet Cytogenet 26:187-190.
51. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. 2001. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61:8-13.
52. Valent A, Benard J, Venuat AM, Silva J, Duverger A, Duarte N, Hartmann O, Spengler BA, Bernheim A. 1999. Phenotypic and genotypic diversity of human neuroblastoma studied in three IGR cell line models derived from bone marrow metastases. Cancer Genet Cytogenet 112:124-129.
53. van der Bliek AM, Baas F, van d, V, Biedler JL, Meyers MB, Ozols RF, Hamilton TC, Joenje H, Borst P. 1988a. Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 48:5927-5932.
54. van der Bliek AM, Kooiman PM, Schneider C, Borst P. 1988b. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 71:401-411.
55. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P. 1993. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53:5269-5273.
56. Wang GQ, Gastman BR, Wieckowski E, Goldstein LA, Rabinovitz A, Yin XM, Rabinowich H. 2001. Apoptosis-resistant mitochondria in T cells selected for resistance to Fas signaling. J Biol Chem 276:3610-3619.
57. Wang SL, Tam MF, Ho YS, Pai SH, Kao MC. 1995. Isolation and molecular cloning of human sorcin a calcium-binding protein in vincristine-resistant HOB1 lymphoma cells. Biochim Biophys Acta 1260:285-293.
58. Zhou DC, Ramond S, Viguie F, Faussat AM, Zittoun R, Marie JP. 1996. Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Int J Cancer 65:365-371.